---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-107253"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-09-14T11:12:01+00:00"
generated_at: "2026-09-14T11:15:17.936845+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Armata gets FDA Breakthrough Therapy designation for AP-SA02 in S. aureus bacteremia

## Summary
- FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
- Designation based on Phase 1b/2a diSArm data: 100% of AP-SA02 patients maintained clinical response vs 75% on placebo at day 28.
- AP-SA02 dosing every 6h for 5 days was well tolerated; no serious adverse events attributed to the drug.
- AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations from the FDA.
- CEO Deborah Birx cites potential to become first antibacterial approved on superiority to standard of care.

## SEC filing metadata
- accession: 0001104659-26-107253
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-09-14T11:12:01+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/0001104659-26-107253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/tm2625289d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-107253
- JSON: https://secwatch.observer/filing/0001104659-26-107253.json
- Plain text: https://secwatch.observer/filing/0001104659-26-107253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.